Industry regulation · Regulatory compliance and changes
Our drug candidates are subject to extensive regulation under the FDA, EMA or comparable foreign authorities, which can be costly and time consuming, cause unanticipated delays or prevent the receipt of the required approvals to commercialize our drug candidates.
Legal and litigation · Litigation and legal proceedings
Any claims or lawsuits relating to infringement of intellectual property rights brought by or against us will be costly and time consuming and may adversely affect our business, financial condition and results of operations. In December 2022, we filed suit against Ascletis Defendants alleging violations of the Defend Trade Secrets Act.
Data and privacy · Cross border data transfer regulations
The GDPR also imposes strict rules on the transfer of personal data to countries outside the EU, which includes the United States and increases the scrutiny that clinical trial sites located in the EEA should apply to transfers of personal data from such sites to countries that are considered to lack an adequate level of data protection.
Legal and litigation · Product liability and warranty claims
We are exposed to product liability, non-clinical and clinical liability risks which could place a substantial financial burden upon us, should lawsuits be filed against us. A successful liability claim or series of claims brought against us could have a material adverse effect on our business, financial condition and results of operations.
Data and privacy · Regulatory investigations and penalties
We are subject to 'fraud and abuse' and similar laws and regulations, and a failure to comply with such regulations or prevail in any litigation related to noncompliance could harm our business, financial condition and results of operations.